MARKET

BIVI

BIVI

Biovie Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.900
-0.120
-5.94%
Closed 16:00 08/09 EDT
OPEN
1.990
PREV CLOSE
2.020
HIGH
2.025
LOW
1.810
VOLUME
42.87K
TURNOVER
48.30K
52 WEEK HIGH
9.00
52 WEEK LOW
1.325
MARKET CAP
47.30M
P/E (TTM)
-0.2098
1D
5D
1M
3M
1Y
5Y
--B. Riley Lowers BioVie's Price Target to $12 from $18 Reflecting More Sharpened Focus of Target Model, Keeps Buy Rating
--B. Riley Lowers BioVie's Price Target to $12 from $18 Reflecting More Sharpened Focus of Target Model, Keeps Buy Rating
MT Newswires · 07/28 10:04
BioVie initiated with an overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan initiated coverage of BioVie (BIVI) with an Overweight rating and $7 price ta...
Seekingalpha · 07/22 15:37
BioVie Shares Rise After Cantor Fitzgerald Begins Coverage at Overweight
MT Newswires · 07/22 12:02
--Cantor Fitzgerald Initiates BioVie at Overweight Rating With $7 Price Target
MT Newswires · 07/22 09:28
BRIEF-BioVie Enters Into Securities Purchase Agreement With Acuitas Group Holdings
BRIEF-BioVie Enters Into Securities Purchase Agreement With Acuitas Group Holdings
Reuters · 07/15 22:23
Longeveron, Adverum top healthcare gainers; while DiaMedica, CytomX lead losers' pack
Gainers: Longeveron (LGVN) +16%. Adverum Biotechnologies (<a href="https...
Seekingalpha · 07/07 14:00
Micro-cap BioVie rises after getting back patent protection for its ascites treatment
BioVie (NASDAQ:BIVI) on Thursday said it had won a patent for its ascites medicine BIV201 which was expected to cover treatment with it in the U.S. until 2036. BIVI stock gained 7.1% to $1.80
Seekingalpha · 06/23 13:28
BioVie Announces Patent Issuance Covering Ascites Treatment With BIV201
BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and
Benzinga · 06/23 12:16
More
No Data
Learn about the latest financial forecast of BIVI. Analyze the recent business situations of Biovie Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
75.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BIVI stock price target is 10.50 with a high estimate of 14.00 and a low estimate of 7.00.
High14.00
Average10.50
Low7.00
Current 1.900
EPS
Actual
Estimate
-8.14-6.11-4.07-2.04
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 15
Institutional Holdings: 1.61M
% Owned: 6.45%
Shares Outstanding: 24.89M
TypeInstitutionsShares
Increased
3
8.98K
New
2
3.04K
Decreased
5
95.82K
Sold Out
3
57.66K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.83%
Pharmaceuticals & Medical Research
-0.22%
Key Executives
Chairman/Director
Terren Peizer
President/Chief Executive Officer/Director
Cuong Do
Chief Financial Officer/Secretary
Joanne Kim
Executive Vice President
Jonathan Adams
Executive Vice President
Clarence Ahlem
Executive Vice President
Penelope Markham
Executive Vice President
Christopher Reading
Other
Joseph Palumbo
Independent Director
Richard Berman
Independent Director
Steven Gorlin
Independent Director
Robert Hariri
Independent Director
James Lang
Independent Director
Sigmund Rogich
Independent Director
Michael Sherman
No Data
No Data
About BIVI
BioVie Inc. is a clinical-stage company pursuing the discovery, development, and commercialization of drug therapies for liver disease. The Company is focused on developing and commercializing BIV201 (continuous infusion terlipressin) an approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The Company is developing BIV201, a treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, nonalcoholic steatohepatitis (NASH) and alcoholism. The Company is also engaged in developing NE3107, an ERK inhibitor that selectively reduces neuroinflammation and insulin resistance.

Webull offers kinds of BioVie Inc stock information, including NASDAQ:BIVI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIVI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BIVI stock methods without spending real money on the virtual paper trading platform.